A Phase 4 interventional study of Aspirin and Aspirin interruption in Antiplatelet Agents and Perioperative Care, sponsored by Kyoto University. Recruiting at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.
Sponsored by Kyoto University · Phase 4, Interventional, and Treatment
The purpose of this study is to evaluate the impact of perioperative aspirin continuation on clinical outcomes in patients with a history of coronary stent implantation who are scheduled for abdominal surgery.
PCI with coronary stent implantation is performed for a huge number of patients with coronary artery disease. Approximately 20% of these patients undergo non-cardiac surgery within three years after PCI. However, there is a scarcity of clinical evidence regarding the efficacy of perioperative aspirin continuation on cardiovascular events.
Kyoto University is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
perioperative aspirin continuation
Drug: Aspirin
Interruption of aspirin 5-7 days before surgery
Drug: Aspirin interruption
perioperative aspirin continuation
Also known as: Aspirin (drug)
Aspirin interruption 5-7 days before surgery
Also known as: Aspirin interruption (drug)
a composite of death or myocardial infarction
the primary endpoint is defined as a composite of all-cause death or myocardial infarction (4th UDMI definition)
Time frame: 30 days
Major bleeding (TIMI major/minor bleeding)
TIMI major/minor bleeding
Time frame: 30 days
Death/Myocardial Infarction (4th UDMI Definition)/Stroke
a composite of Death, Myocardial Infarction (4th UDMI Definition), or Stroke
Time frame: 30 days
Death/Myocardial Infarction (4th UDMI Definition)/Myocardial Injury (MINS)
a composite of Death, Myocardial Infarction (4th UDMI Definition), or Myocardial Injury (MINS)
Time frame: 30 days
Myocardial Infarction (4th UDMI Definition)/Myocardial Injury (MINS)
a composite of Myocardial Infarction (4th UDMI Definition), or Myocardial Injury (MINS)
Time frame: 30 days
Death/Myocardial Infarction (ARC-2 Definition)/Stroke
a composite of Death, Myocardial Infarction (ARC-2 Definition), orStroke
Time frame: 30 days
Death
all-cause death
Time frame: 30 days
Cardiovascular Death
cardac and vascular death
Time frame: 30 days
Myocardial Infarction (4th UDMI Definition)
Myocardial Infarction defined by 4th UDMI Definition
Time frame: 30 days
Myocardial Infarction (ARC-2 Definition)
Myocardial Infarction defined by ARC-2 Definition
Time frame: 30 days
Myocardial Infarction (SCAI Definition)
Myocardial Infarction defined by SCAI Definition
Time frame: 30 days
Myocardial Infarction (modified POISE-2 Definition)
Myocardial Infarction defined by modified POISE-2 Definition
Time frame: 30 days
Myocardial Injury (MINS)
Myocardial Injury (MINS) is defined as cardiac enzyme elevation without symptoms or ECG changes.
Time frame: 30 days
Stent Thrombosis (ARC Definition)
Stent thrombosis defined by ARC definition
Time frame: 30 days
Stroke
Sudden neurological disorder that persists for at least 24 hours and is caused by blockage of cerebral blood flow due to bleeding or ischemia.
Time frame: 30 days
Cerebral Infarction
Sudden neurological disorder that persists for at least 24 hours and is caused by infarction.
Time frame: 30 days
Cerebral Hemorrhage
Sudden neurological disorder that persists for at least 24 hours and is caused by cerebral bleeding.
Time frame: 30 days
Coronary Revascularization
PCI or CABG
Time frame: 30 days
Major Bleeding (BARC classification)
Major bleeding defined by BARC classification
Time frame: 30 days
Major Bleeding (modified POISE-2 classification)
Major bleeding defined by modified POISE-2 classification
Time frame: 30 days
Major Bleeding (GUSTO classification)
Major bleeding defined by GUSTO classification
Time frame: 30 days
Fatal Bleeding
Fatal bleeding within 30 days after abdominal surgery
Time frame: 30 days
Bleeding Volume During Non-Cardiac Surgery
bleeding volume during abdominal surgery
Time frame: 30 days
Transfusion
transfusion during and after surgery
Time frame: 30 days
Reoperation
any reoperation
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kyoto University